Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Carcinoma Metastatic in the Bone|Circulating Tumor Cell Count|Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Positive|Stage IV Breast Cancer
Interventions: BIOLOGICAL: Denosumab|OTHER: Laboratory Biomarker Analysis
Sponsor: Northwestern University
Collaborators: Amgen|National Cancer Institute (NCI)